Julien Viot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julien Viot has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Gautheret
Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France
17 shared publications - Andrey A. Yurchenko
INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France
16 shared publications - Antoine Hollebecque
Gustave Roussy, Villejuif, France
16 shared publications - Benjamin Besse
Department of Cancer Medicine, Gustave Roussy, Villejuif, France
16 shared publications - Guillaume Grisay
CHU Helora Jolimont, La Louviere, Belgium
16 shared publications - Ismael Padioleau
INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France
16 shared publications
Latest Publications
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation du profil d’expression des rétrovirus endogènes dans les cancers colorectaux métastatiques
Le cancer métastatique demeure une maladie incurable et mortelle. La compréhension des déterminants de la propagation métastatique et de l’environnement des métastases est essentielle pour améliorer notre connaissance du cancer et ouvrir de nouvelles voies thérapeutiques. La découverte de séquences intergéniques impliquées dans la régulation génétique des cancers et leur corrélation avec le système immunitaire ont ouvert de nouvelles perspectives de recherche. Ces séquences, appelées rétrovirus endogènes humains (HERV), constituent une nouvelle voie de recherche inexplorée dans les cancers métastatiques, notamment colorectaux.Nous avons exploré la génétique des cancers métastatiques, notamment des cancers colorectaux métastatiques hépatiques, à l'aide de séquençage haut débit de l'ADN, de l'ARN (RNA-seq), de l'ARN en cellule unique, et de la protéomique. La cohorte METAPRISM, comprenant 1 031 tumeurs métastatiques réfractaires, a permis d'identifier de nouveaux marqueurs de résistance et des signatures mutationnelles spécifiques. Parallèlement, l'impact des HERV sur le microenvironnement tumoral et la réponse immunitaire a été évalué à partir d'une cohorte de plus de 400 échantillons, incluant des données publiques, ainsi que d'une nouvelle cohorte de 200 échantillons de cancers colorectaux métastatiques, BIOMIROXLes analyses ont révélé des altérations récurrentes de gènes tels que PTEN et RB1, et des amplifications de MYC, qui contribuent à la résistance aux traitements. En parallèle, l'étude des HERV a montré que certains loci, particulièrement ceux de la famille HERV-H, sont exprimés de manière significative dans les tumeurs colorectales par rapport aux tissus sains, et présentent des valeurs pronostiques après la résection des métastases hépatiques. Les analyses ont mis en évidence des interactions entre les HERV et le microenvironnement immunitaire, révélant des associations avec des modifications des populations de lymphocytes T et des voies immunitaires. En outre, l'expression de CD226 sur les cellules T CD8+ infiltrant les métastases hépatiques s'est avérée être un facteur pronostique indépendant, associé à une potentielle restauration de la réponse immunitaire par des cytokines telles que l'IL-15.Ce travail démontre l'importance des analyses intégratives pour révéler des mécanismes de résistance complexes et propose des approches innovantes pour la personnalisation des traitements en oncologie de précision. Les résultats ouvrent de nouvelles perspectives pour le développement de thérapies ciblées basées sur les signatures moléculaires et immunitaires spécifiques des tumeurs métastatiques.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation du profil d’expression des rétrovirus endogènes dans les cancers colorectaux métastatiques
Le cancer métastatique demeure une maladie incurable et mortelle. La compréhension des déterminants de la propagation métastatique et de l’environnement des métastases est essentielle pour améliorer notre connaissance du cancer et ouvrir de nouvelles voies thérapeutiques. La découverte de séquences intergéniques impliquées dans la régulation génétique des cancers et leur corrélation avec le système immunitaire ont ouvert de nouvelles perspectives de recherche. Ces séquences, appelées rétrovirus endogènes humains (HERV), constituent une nouvelle voie de recherche inexplorée dans les cancers métastatiques, notamment colorectaux.Nous avons exploré la génétique des cancers métastatiques, notamment des cancers colorectaux métastatiques hépatiques, à l'aide de séquençage haut débit de l'ADN, de l'ARN (RNA-seq), de l'ARN en cellule unique, et de la protéomique. La cohorte METAPRISM, comprenant 1 031 tumeurs métastatiques réfractaires, a permis d'identifier de nouveaux marqueurs de résistance et des signatures mutationnelles spécifiques. Parallèlement, l'impact des HERV sur le microenvironnement tumoral et la réponse immunitaire a été évalué à partir d'une cohorte de plus de 400 échantillons, incluant des données publiques, ainsi que d'une nouvelle cohorte de 200 échantillons de cancers colorectaux métastatiques, BIOMIROXLes analyses ont révélé des altérations récurrentes de gènes tels que PTEN et RB1, et des amplifications de MYC, qui contribuent à la résistance aux traitements. En parallèle, l'étude des HERV a montré que certains loci, particulièrement ceux de la famille HERV-H, sont exprimés de manière significative dans les tumeurs colorectales par rapport aux tissus sains, et présentent des valeurs pronostiques après la résection des métastases hépatiques. Les analyses ont mis en évidence des interactions entre les HERV et le microenvironnement immunitaire, révélant des associations avec des modifications des populations de lymphocytes T et des voies immunitaires. En outre, l'expression de CD226 sur les cellules T CD8+ infiltrant les métastases hépatiques s'est avérée être un facteur pronostique indépendant, associé à une potentielle restauration de la réponse immunitaire par des cytokines telles que l'IL-15.Ce travail démontre l'importance des analyses intégratives pour révéler des mécanismes de résistance complexes et propose des approches innovantes pour la personnalisation des traitements en oncologie de précision. Les résultats ouvrent de nouvelles perspectives pour le développement de thérapies ciblées basées sur les signatures moléculaires et immunitaires spécifiques des tumeurs métastatiques.
- Open Access
Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France
Objectives: This study aimed to fill the data gap regarding the prevalence of germline (g) BRCA1/2 mutations in patients with metastatic breast cancer (mBC) in France. Methods: A prospective gBRCA1/BRCA2 mutation analysis was proposed to all patients with mBC treated in seven French centers between 19 February and 30 November 2015. The BRCA TrueTM test (Pathway Genomics®, San Diego, CA, USA) analyzed the coding and flanking regions of BRCA1 and BRCA2 genes using next-generation sequencing, Sanger sequencing, and multiplex ligation-dependent probe amplification. Results: Among 407 included mBC patients, 11 (2.7%) carried pathogenic gBRCA1/2 mutations. Of these, five (45%) would not have met standard criteria for genetic screening. Compared with non-carriers, gBRCA1/2 carriers were significantly younger at mBC diagnosis (47.5 vs. 60.7 years, p = 0.0006), had higher-grade tumor histology (p = 0.044), and had a higher rate of contralateral recurrence (36.4% vs. 11.6%, p = 0.035), with comparable adjusted survival (median overall survival 74.9 vs. 100.1 months, p = 0.97). Variants of uncertain significance were identified in 17 (4.2%) patients. Conclusions: The 2.7% prevalence of gBRCA1/2 mutations in this prospective French mBC cohort was relatively low. Nearly half of the mutation carriers would not have been routinely referred for oncogenetic counseling, underscoring the potential value of broader genetic screening in this population.
Open AccessGermline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France
Objectives: This study aimed to fill the data gap regarding the prevalence of germline (g) BRCA1/2 mutations in patients with metastatic breast cancer (mBC) in France. Methods: A prospective gBRCA1/BRCA2 mutation analysis was proposed to all patients with mBC treated in seven French centers between 19 February and 30 November 2015. The BRCA TrueTM test (Pathway Genomics®, San Diego, CA, USA) analyzed the coding and flanking regions of BRCA1 and BRCA2 genes using next-generation sequencing, Sanger sequencing, and multiplex ligation-dependent probe amplification. Results: Among 407 included mBC patients, 11 (2.7%) carried pathogenic gBRCA1/2 mutations. Of these, five (45%) would not have met standard criteria for genetic screening. Compared with non-carriers, gBRCA1/2 carriers were significantly younger at mBC diagnosis (47.5 vs. 60.7 years, p = 0.0006), had higher-grade tumor histology (p = 0.044), and had a higher rate of contralateral recurrence (36.4% vs. 11.6%, p = 0.035), with comparable adjusted survival (median overall survival 74.9 vs. 100.1 months, p = 0.97). Variants of uncertain significance were identified in 17 (4.2%) patients. Conclusions: The 2.7% prevalence of gBRCA1/2 mutations in this prospective French mBC cohort was relatively low. Nearly half of the mutation carriers would not have been routinely referred for oncogenetic counseling, underscoring the potential value of broader genetic screening in this population.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S24 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
These figures provide complementary information for the figures presented in the main text and illustrations of the methods section.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S24 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
These figures provide complementary information for the figures presented in the main text and illustrations of the methods section.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S11 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
These tables present clinical data, sample data, whole-exome and transcriptome sequencing results, literature references, and external data sources that were used for the analyses presented in the main text.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S11 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
These tables present clinical data, sample data, whole-exome and transcriptome sequencing results, literature references, and external data sources that were used for the analyses presented in the main text.
- Open Access
- 16 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 116, 105727
Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastases
- 16 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 116, 105727
Open AccessDeciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastases
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S24 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These figures provide complementary information for the figures presented in the main text and illustrations of the methods section.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S24 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These figures provide complementary information for the figures presented in the main text and illustrations of the methods section.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S11 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These tables present clinical data, sample data, whole-exome and transcriptome sequencing results, literature references, and external data sources that were used for the analyses presented in the main text.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S11 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These tables present clinical data, sample data, whole-exome and transcriptome sequencing results, literature references, and external data sources that were used for the analyses presented in the main text.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S11 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These tables present clinical data, sample data, whole-exome and transcriptome sequencing results, literature references, and external data sources that were used for the analyses presented in the main text.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S11 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These tables present clinical data, sample data, whole-exome and transcriptome sequencing results, literature references, and external data sources that were used for the analyses presented in the main text.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S24 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These figures provide complementary information for the figures presented in the main text and illustrations of the methods section.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S24 from Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
These figures provide complementary information for the figures presented in the main text and illustrations of the methods section.
- Open Access
Exploring a large cancer cell line RNA-sequencing dataset with k-mers
Analyzing the immense diversity of RNA isoforms in large RNA-seq repositories requires laborious data processing using specialized tools. Indexing techniques based on k-mers have previously been effective at searching for RNA sequences across thousands of RNA-seq libraries but falling short of enabling direct RNA quantification. We show here that RNAs queried in the form of k-mer sets can be quantified in seconds, with a precision akin to that of conventional RNA quantification methods. We showcase several applications by exploring an index of the Cancer Cell Line Encyclopedia (CCLE) collection consisting of 1019 RNA-seq samples. Non-reference RNA sequences such as RNAs harboring driver mutations and fusions, splicing isoforms or RNAs derived from repetitive elements, can be retrieved with high accuracy. Moreover, we show that k-mer indexing offers a powerful means to reveal variant RNAs induced by specific gene alterations, for instance in splicing factors. A web server allows public queries in CCLE and other indexes: https://transipedia.fr . Code is provided to allow users to set up their own server from any RNA-seq dataset.
Open AccessExploring a large cancer cell line RNA-sequencing dataset with k-mers
Analyzing the immense diversity of RNA isoforms in large RNA-seq repositories requires laborious data processing using specialized tools. Indexing techniques based on k-mers have previously been effective at searching for RNA sequences across thousands of RNA-seq libraries but falling short of enabling direct RNA quantification. We show here that RNAs queried in the form of k-mer sets can be quantified in seconds, with a precision akin to that of conventional RNA quantification methods. We showcase several applications by exploring an index of the Cancer Cell Line Encyclopedia (CCLE) collection consisting of 1019 RNA-seq samples. Non-reference RNA sequences such as RNAs harboring driver mutations and fusions, splicing isoforms or RNAs derived from repetitive elements, can be retrieved with high accuracy. Moreover, we show that k-mer indexing offers a powerful means to reveal variant RNAs induced by specific gene alterations, for instance in splicing factors. A web server allows public queries in CCLE and other indexes: https://transipedia.fr . Code is provided to allow users to set up their own server from any RNA-seq dataset.